Technical analysis of Legend Biotech Corporation (LEGN): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM).
Price Performance
| 1 month | +16.48% |
| 3 months | +13.07% |
| Year-to-date | -0.51% |
| 1 year | -33.24% |
| 3 years | -67.21% |
| 5 years | -58.20% |
52-Week Range
| 52-week High | $37.50 |
| 52-week Low | $16.24 |
| Avg Volume (90d) | 2.2M |
Technical Indicators
| SMA 50 | $19.55 |
| SMA 200 | $22.13 |
| Beta | 0.08 |
| 30-day Volatility (annualised) | 52.4% |
| Price vs SMA 50 | +10.6% |
| Price vs SMA 200 | -2.3% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-12 | $21.74 | |
| 2026-01 | $17.50 | -19.5% |
| 2026-02 | $19.00 | +8.6% |
| 2026-03 | $18.09 | -4.8% |
| 2026-04 | $23.52 | +30.0% |
| 2026-05 | $27.16 | +15.5% |
| 2026-06 | $28.88 | +6.3% |
| 2026-07 | $18.55 | -35.8% |
| 2026-08 | $20.78 | +12.0% |
| 2026-09 | $19.89 | -4.3% |
| 2026-10 | $21.63 | +8.7% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-11-10 | $0.01 | $361M |
| 2026-08-11 | $0.12 | $356M |
| 2026-05-12 | $-0.02 | $307M |
| 2026-03-10 | $-0.17 | $308M |
| 2025-11-12 | $-0.13 | $274M |
| 2025-08-11 | $-0.11 | $229M |
| 2025-05-13 | $-0.23 | $194M |
Price
| Price | $21.63 (closing price, October 30, 2026) |
| Market Cap | $4.0B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.29 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.23 |
| Current Ratio | 3.04 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 2.46 |